AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01277185 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High Calcium Diet
Description: The basal diet will contain 600 mg of Ca per day and constant sufficient amounts of all other nutrients. Additional Ca will be given unfortified beverages served three times per day. Teens will be randomized to a higher (1100-2300mg/d)level of calcium in the first camp followed by the opposite (lower calcium diet)regime in the second camp.
Study NCT02096354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RRx-001
Study NCT02096354 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regorafenib
Study NCT02096354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: To be dosed after RRx-001 or regorafenib
Study NCT02096354 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: To be dosed after RRx-001 or regorafenib
Study NCT04593745 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Intraocular pressure measurment
Description: Intraocular pressure measurmentt using iCare devise: TONOPEN
Study NCT03162627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: Dose Escalation Phase Starting Dose: 50 mg by mouth twice a day on Days 1-28.~Dose Expansion Phase Starting Dose: Maximum tolerated dose from Dose Escalation Phase.
Study NCT03162627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Dose Escalation Phase Starting Dose: 150 mg by mouth twice a day on Days 1-28.~Dose Expansion Phase Starting Dose: Maximum tolerated dose from Dose Escalation Phase.
Study NCT04402216 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Child Life-led preparation
Description: Support from a certified child life specialist in preparation for MRI
Study NCT04402216 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MRI preparation video
Description: A descriptive video about what to expect when undergoing MRI
Study NCT04402216 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: KindVR Virtual Reality MRI Preparation Experience
Description: A VR experience to prepare pediatric patients for MRI, to be used in addition to support from a certified child life specialist
Study NCT03375437 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Blood and tumor samples
Description: FFPE tumor block (archival or a dedicated freshly collected tumor biopsy) will be collected for all enrolled patients and centralized.~Blood sampling for Translational Research (optional) (2\*10mL EDTA)
Study NCT03900650 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High provocation manipulation
Description: Participants will engage in a laboratory task and will then report their emotions following the task.
Study NCT03900650 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low provocation manipulation
Description: Participants will engage in a laboratory task and will then report their emotions following the task.
Study NCT03598608 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Favezelimab
Description: Administered as an IV infusion Q3W
Study NCT02379156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midodrine Hydrochloride
Description: Midodrine hydrochloride is an approved medication used to treat low blood pressure. We are using a standard dose of 10 mg (tablet) only one time to determine if the vascular-constricting effects of this drug will help keep warm blood closer to the body's core and improve the ability to maintain Tcore in a cool environment (off-label use). A physician will administer the drug once before the cool thermal challenge in subjects with tetraplegia only (Visit 2).
Study NCT02379156 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cool Temperature
Description: Subjects will be exposed to a routinely encountered cool temperature (64° F) for up to to 2 hours depending on the vital signs (BP, HR, Tcore) and tolerance (comfort).
Study NCT03900650 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alcoholic beverage
Description: Participants will consume an alcoholic beverage (vodka mixed with fruit juice) that is the equivalent of 3-4 standard alcoholic drinks based on their body weight.
Study NCT03900650 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non-alcoholic beverage
Description: Participants will consume a nonalcoholic beverage (fruit juice) that is the isovolemic equivalent of 3-4 standard alcoholic drinks based on their body weight.
Study NCT03508583 — intervention group
Intervention type: OTHER
Intervention: Participation
Description: The mpoc 56 and mpoc 20 will be field-tested with a sample of 300 parents of children with disabilities residing in the Turkey.~Professionals working with children with disabilities will be assessed with MPOC SP questionnaires
Study NCT04573504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Augmentin/Flagyl or Augmentin/Clindamycin
Description: Women who suffer a severe vaginal laceration at Prentice Women's Hospital will be randomized to receive 5-days of oral antibiotics or placebo pills after getting a standard one-time dose of IV antibiotics at the time of repair.
Study NCT04573504 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04148209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07081532
Description: Participants will receive single ascending doses PF-07081532
Study NCT04148209 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo
Study NCT04569032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: 1.8 mg/kg administered intravenously (IV; into the vein) on Day 1 of each 21 -day cycle
Study NCT04569032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 750 mg/m\^2 administered intravenously (IV; into the vein) on Day 1 of each 21 -day cycle
Study NCT04569032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: 50 mg/m\^2 administered intravenously (IV; into the vein) on Day 1 of each 21 -day cycle
Study NCT04569032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: 100 mg daily administered orally on Days 1-5 of each cycle
Study NCT00778544 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amoxicillin-clavulanic acid 600 mg- 42.9 mg/ 5 mL oral suspension
Study NCT01969409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: i.v. rituximab given on two occasions 14 days apart.
Study NCT03968861 — intervention group
Intervention type: DRUG
Intervention: Xenon
Description: Inhaled xenon gas given via purposely designed ventilator
Study NCT04290650 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Modified CBT for insomnia
Description: Nurses who are working closely with the patients around the clock will perform an adjusted and modified version of CBT for sleep disturbances, in addition to standard evidence based treatment for psychosis and affective disorders as per today.
Study NCT04290650 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treatment as usual
Description: All patients on the two other psychosis wards will receive standard evidence based treatment for psychosis and affective disorders as per today.
Study NCT04755543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LP002
Description: 600mg or 900 mg by intravenous (IV) infusion on Day 1, every 2 weeks (Q2W).
Study NCT01969409 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects randomized to placebo will receive two i.v. doses of 5% dextrose in water (D5W) in the same schedule as the rituximab subjects. The D5W and rituximab preparations will be indistinguishable.
Study NCT05068583 — intervention group
Intervention type: OTHER
Intervention: Blood Draw
Description: Blood draw at baseline, disease evaluation time point, and pre and post surgery and/or radiation.
Study NCT03000881 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard adhesive
Description: This is a standard adhesive (hydrocolloid)
Study NCT03000881 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: New adhesive strip
Description: This is a newly developed adhesive strip
Study NCT04539288 — intervention group
Intervention type: OTHER
Description: There is no intervention in this study.
Study NCT00585312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: celecoxib, 16 mg/kg/day, for 5 years
Study NCT00585312 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Masked, placebo comparator
Study NCT04755543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 50mg/m2 IV on Day 1, Q2W
Study NCT01202084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol/Fluticasone
Study NCT01202084 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Foraseq®
Study NCT01202084 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone
Study NCT03898427 — intervention group
Intervention type: DEVICE
Intervention: Wrist Actigraphy Devices
Description: A watch-like wearable sensor
Study NCT03898427 — intervention group
Intervention type: DEVICE
Intervention: Polysomnography
Description: Sleep Monitor
Study NCT03898427 — intervention group
Intervention type: DEVICE
Intervention: Videography
Description: Thermal Camera
Study NCT02474498 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EMD
Description: During flap access surgery, the granulation tissue will be removed and the root surfaces will be carefully instrumented with ultrasonic and hand instruments. The furcation defects in this group will receive the application of enamel matrix derivative (EMD - Emdogain® Straumann, Basel, Switzerland).
Study NCT02474498 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: βTCP/HA
Description: During flap access surgery, the granulation tissue will be removed and the root surfaces were carefully instrumented with ultrasonic and hand instruments. The furcation will be filled with a bone substitute consisting of beta tricalcium phosphate/hydroxyapatite (βTCP/HA- Bone Ceramic® Straumann, Basel, Switzerland)
Study NCT02474498 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Flap access surgery
Description: In the furcation sites, during flap access surgery, the granulation tissue will be removed and the root surfaces will be carefully instrumented with ultrasonic and hand instruments.
Study NCT04755543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: 2000 mg/m2 IV continuous infusion over 48 hours from Day 1, Q2W
Study NCT04755543 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OH2 oncolytic virus
Description: 106 or 107 or 108 CCID50/mL by intra-tumoral injection, Q2W
Study NCT03453216 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: neuropsychological tests
Description: Part 1: to determine the cognitive capacity, the subjects undergo different neuropsychological tests To determine individual characteristics children, adolescents and adults complete self-assessment questionnaires .~Adults spend a semi-directive interview. Part 2: while the subject 1 (S1) is installed in the MRI, he perform behavioral tasks with the subject 2 (S2) (familiar peer of the same age ± 2 years) installed in an adjacent room, alternating periods when S1 is observed by S2 (condition Social) and periods when S1 is not observed by S2 (condition Alone).
Study NCT04942145 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: virtual reality in dental patients
Description: The behavioral anxiety response of dental patients (with and without virtual reality) related to psychological factors is studied.~Participants self-complete the questionnaires
Study NCT02053220 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Colo-Ad1
Description: Oncolytic virus
Study NCT04942145 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: virtual reality in dental patients
Description: The behavioral anxiety response of dental patients (with and without virtual reality) related to psychological factors is studied.~Participants self-complete the questionnaires
Study NCT01833078 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ghrelin
Description: ghrelin administration subcutaneously for 7 days
Study NCT02652247 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: molecular analysis of exhaled breath condensate
Study NCT02652247 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: molecular analysis of mini-bronchoalveolar lavage (BAL) aspirate
Study NCT02508116 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: CYP2C19 genotyping
Description: The study utilizes a genotyping device, SpartanRx™ (Spartan Bioscience, Ottawa, Canada) that provides identification of a patient's CYP2C19 \*2, \*3, and \*17 genotypes determined from genomic DNA from a buccal swab sample with 1 hour turnaround time
Study NCT02056652 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bioteque cup pessary
Study NCT03889691 — intervention group
Intervention type: PROCEDURE
Intervention: Third molar surgery
Description: Surgical extraction of impacted lower third molar tooth under local anesthesia
Study NCT00005858 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LMB-9 immunotoxin
Study NCT01907581 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Quality of life questionnaires
Study NCT00177541 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biofeedback, pelvic floor muscle training, fMRI
Description: Biofeedback, pelvic floor muscle training, fMRI
Study NCT04559152 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc Supplementation Group
Description: Enrolled subjects received zinc capsule 20mg daily in the morning after meal for 12 weeks
Study NCT04559152 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Group
Description: Enrolled subjects received placebo tablet, which was inserted into capsule of the same shape and color as zinc capsule, daily in the morning after meal for 12 weeks
Study NCT00556361 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: 2 mg/Kg IV saline within 5 minutes of initiation of Cardiopulmonary bypass
Study NCT00556361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine
Description: 2 mg/Kg IV within 5 minutes of cardiopulmonary bypass
Study NCT01096082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium Carbonate
Description: 300 mg tablets, starting dose 300 mg/day
Study NCT01096082 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Similar shape, color and taste and the same number of tablets from the experimental group
Study NCT02652247 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: molecular analysis of bronchoalveolar lavage (BAL) aspirate
Study NCT04463329 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional two-operator versus single operator using Jedi grip axillary brachial plexus blockage
Description: on goup C, operator used the probe and needle with different hands while an assistant controlling the syringe to aspirate or inject local anesthetic. On Group J single operator controlled the probe with one hand while controlling the needle and the syringe on the other hand with the Jedi technique. The needle was held between the index finger and the middle phalanx of the middle finger, and the syringe was held with fingers 4 and 5, with the plunger part to the thumb in the palm.
Study NCT01734187 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fermented Cinnamon Vine Powder
Description: Fermented Cinnamon Vine Powder (30g/day)
Study NCT03169543 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep deprivation
Description: 36-hours total sleep deprivation
Study NCT02650635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT02650635 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02650635 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Given SC
Study NCT02650635 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02650635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLR8 Agonist VTX-2337
Description: Given SC
Study NCT00569465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arginine
Description: 1200 mg, once a day
Study NCT00569465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylcysteine
Description: 600 mg twice a day
Study NCT00569465 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 vials a day
Study NCT03231657 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Placental biomarkers
Description: sFlt1 and P1GF levels and sFlt1/PlGF ratio
Study NCT04830085 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hysterectomy
Description: Hysterectomy (abdominal, vaginal or laparoscopic)
Study NCT04830085 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hysterectomy
Description: Hysterectomy (abdominal, vaginal or laparoscopic)
Study NCT01972152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lilly Glucagon(TM) 1 mg
Study NCT01362790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentostatin
Description: Regimen A: Cycle 1: 4 mg/m\^2 on days 1, 5 and 9 of 30 day cycle Cycles 2-4: 4 mg/m\^2 on day 1 of 21 day cycle Regimen B: Cycle 1: 4 mg/m\^2 or 2 mg/m\^2 on days 1, 5, 9, 13 and 17 of 38 day cycle Cycles 2-6: 4 mg/m\^2 on days 1 and 5 of 25 day cycle
Study NCT01362790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Regimen A:Cycle 1: 200 mg/day on days 1-12 of 30 day cycle Cycles 2-4: 200 mg/day on days 1-4 of 21 day cycle Regimen B:Cycle 1: 200 mg/day on days 1-20 of 38 day cycle Cycles 2-4: 200 mg/day on days 1-8 of 25 day cycle
Study NCT01362790 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SS1(dsFv)PE38 - lot 073I0809
Description: Regimen A: Cycle 1: Cycle 1: 35mcg/kg days 10, 12 and 14 Cycles 2-4: Days 2, 4 and 6, for a maximum of six treatment cycles Regimen B: Cycle 1: 35mcg/kg days 18, 20 and 22 Cycles 2-4: (Days 6, 8 and 10), for a maximum of six treatment cycles
Study NCT01362790 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SS1(dsFv)PE38 - lot FIL129J01
Description: Regimen A:~Cycle 1: Cycle 1:35mcg/kg or 25 mcg/kg days 10, 12 and 14 Cycles 2-4: Days 2, 4 and 6, for a maximum of six treatment cycles
Study NCT02531256 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LMA Protector
Description: Insertion of airway device for airway management during gynaecological procedure
Study NCT02951481 — intervention group
Intervention type: BEHAVIORAL
Intervention: Systematic evaluation by an ID expert.
Description: Specific bundle of measures:~1. Systematic evaluation of all patients diagnosed with CDI by an Infectious Disease expert To ensure compliance with clinical practice guidelines about specific treatment for CDI, depending on the severity of the episode and the existence of previous episodes and to optimize concomitant antibiotic therapy (antimicrobial stewardship).~2. To ensure appropriate monitoring during the period of greatest risk of relapse in order to reduce as far as possible, the number of relapses. Personalized assistance by telephone or by email for early consultation in case of recurrence of symptoms or need for a new antibiotic course.
Study NCT01313533 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyarginine
Description: Vein soak treated with polyarginine
Study NCT01734187 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (30g/day)
Study NCT04194658 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole 2.5mg
Description: Pretreatment letrozole 12.5 mg for 2 days prior to misoprostol.
Study NCT01313533 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vein soak treated with Lactated Ringers Solution
Description: Vein soak
Study NCT03531580 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Brain imaging using magnetic resonance imaging, using several MRI sequences: structural imaging (grey matter, using T1-imaging), cerebral perfusion using arterial spin labeling), functional and effective connectivity (using resting-state functional MRI), white matter tracts (using diffusion imaging), white matter lesions (using Fluid-attenuated inversion recovery MRI (FLAIR)) and microbleeds (using Susceptibility weighted imaging (SWI))
Study NCT00917501 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OMega 3
Description: Individual omega-3 capsules contain 400 mg EPA and 200 mg DHA taken twice a day
Study NCT00917501 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo given twice a day which will be compared to Omega 3
Study NCT01146821 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 0.20 gm/kg fish oil
Description: Group 2: 7 patients will receive 0.20gm/kg of ideal body weight \[IBW\] fish oil in addition to standard care